Climb Bio, Inc. (CLYM) intrinsic value & 10-year financials
Climb Bio, Inc. (CLYM) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $9.82
- Market cap
- $665.9M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -31.5%
- Free cash flow (FY2025)
- -$54.5M
CLYM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$59.9M | -$0.88 | -$54.5M | — | -54.3% |
| FY2024 | — | -$73.9M | -$1.53 | -$20.2M | — | -117.6% |
| FY2023 | $48.0K | -$35.1M | -$1.30 | — | -83906.2% | -80.7% |
| FY2022 | — | -$45.2M | -$1.72 | — | — | -43.9% |
| FY2021 | — | -$47.5M | -$4.24 | — | — | -29.7% |
| FY2020 | — | -$20.7M | — | — | — | 137.0% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Climb Bio, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Climb Bio, Inc. has historically struggled to out-earn its cost of capital, averaging just -65.2% ROIC.
Climb Bio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Climb Bio, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.